checkAd

Nature Publication Reports Favorable Clinical Trial Results of BioNTech's Individualized Cancer Vaccine IVAC® MUTANOME

Nachrichtenquelle: GlobeNewswire
05.07.2017, 19:05  |  755   |   |   

BioNTech AG / Nature Publication Reports Favorable Clinical Trial Results of BioNTech's Individualized Cancer Vaccine IVAC® MUTANOME . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.

- First-ever clinical study demonstrates personalized RNA-based vaccine using mutant neo-epitopes as antigens activates immune system against individual mutations and exerts anti-cancer activity -

MAINZ, Germany, July 05, 2017 (GLOBE NEWSWIRE) -- BioNTech AG, a fully-integrated biotechnology company pioneering individualized cancer immunotherapy, today announced Phase I trial results demonstrating its IVAC® MUTANOME, an individualized RNA vaccine based on patient-specific mutations, induces strong immunogenicity as well as promising anti-tumor activity in high-risk patients with late-stage melanoma. Additionally, in this early trial, a majority of patients showed prolonged progression-free survival in comparison to historical controls. The first-in-human study applied a process covering the comprehensive identification of individual mutations from routine tumor biopsies to next generation sequencing, the computational prediction of potential neo-epitopes as vaccine targets, and the design and manufacturing of an RNA vaccine encoding multiple neo-epitopes unique for each patient. The data, published today online in Nature, were obtained from research conducted in collaboration with clinical partners and the translational research institute, TRON.

In the first-in-human application of a personalized RNA-based vaccine approach, 13 patients with melanoma were treated. The vaccine boosted immunity against multiple tumor antigens in all patients, and infiltration of vaccine-induced T-cells into tumors was observed in two patients. Eight of the 13 patients remained tumor-free at 23 months; five patients had tumor relapses before starting neo-epitope vaccination. Two of these patients experienced objective responses after neo-epitope vaccination and one patient had a complete response after sequential administration of neo-epitope vaccination and anti-PD-1 therapy.

Seite 1 von 3


Diesen Artikel teilen

0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

Nature Publication Reports Favorable Clinical Trial Results of BioNTech's Individualized Cancer Vaccine IVAC® MUTANOME BioNTech AG / Nature Publication Reports Favorable Clinical Trial Results of BioNTech's Individualized Cancer Vaccine IVAC® MUTANOME . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of …